The Chamber of Deputies discusses medical cannabis in Brazil


The Brazilian Senate is discussing the regulation of grass for medical purposes

Two days ago, the Brazilian Federal Senate held a public hearing on medical cannabis. The health regulatory agency of Brazil (Anvisa) places the issue of legalization on the agenda and the Social Security Committee of the House of Representatives also submits the debate in plenary. The Commission for Human Rights and Participatory Legislation in Brazil (CCH) has scheduled this public hearing on the regulation, enforcement and taxation of cannabis for medical purposes and industrial hemp.

The idea is to establish a complete standard for medical cannabis and industrial hemp in Brazil, based on legislation in the US states and Uruguay.

Convened by the MP Eduardo Costa the members present at the meeting were numerous: The Minister of Citizenship, Osmar Terra , who spoke before the Commission on Human Rights and Participatory Legislation of the Senate, as well as Carlos Gourlart , representative of the Ministry of Agriculture, William Dib , President of the National Health Surveillance Agency, Leandro Ramires , representative of the Brazilian Association of Patients with Medicinal Cannabis (Ama + ME), Rodrigo Mesquita , Reforma lawyer, Legal Network for Drug Policy Reform, Carlos Vital Côrrea Lima , President of the Federal Council of Medicine (CFM) and Ricardo Ferreira, Representative of the Brazilian Society of Cannabis Studies.

Read also
France lags behind on legalization

Anvisa must regulate medicinal cannabis production until November

Dr. William Dib (doctor and politician) said Tuesday that the agency should legislate the production, cultivation, import and transport of cannabis for medicinal use until November 2019. The public consultation will last until August 20. After that, Anvisa will compile the suggestions within 30 to 40 days. The body will then vote on the proposed regulation.

Currently, only patients with legal authorization can produce or import cannabis products for therapeutic purposes. Decisions are individual for each patient. With regulation, production and importation will be accessible to other patients.

Anvisa does not discuss recreational use and drug release, we only discuss medical use.

Tags : BrazilLawPolitic